Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous NKT Cells in Metastatic Melanoma
NCT02619058Phase 1Unknown
- Sponsor
- Peking University Cancer Hospital & Institute
- Start
- Oct 2015
- Primary completion
- Oct 2016
- Modality
- Lymphokine-Activated Killer Cells, CAR-NK Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of autologous natural killer T cells in melanoma (3 arms), sponsored by Peking University Cancer Hospital & Institute. Primary endpoint: Dose Limiting Toxicity at 252 days. Status: unknown.
02
Drugs
autologous natural killer T cells
03
Conditions
melanoma
Beyond the preview
Go deeper on NCT02619058.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02619058.